Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone metastases: pathogenesis and treatment with diphosphonates]

J J Body1

  • 1Clinique des soins supportifs et Clinique des maladies osseuses, Institut J. Bordet, Université libre de Bruxelles.

Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique
|January 1, 1997
PubMed
Summary

Tumor-induced osteolysis and hypercalcemia involve osteoclasts and parathyroid hormone-related protein (PTHrP). Pamidronate at 90 mg is optimal for treating these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone strain index improves 10-year fracture risk prediction beyond bone mineral density and FRAX® in community-dwelling older women: A study of the FRISBEE cohort.

Bone·2026
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Selection for treatment of patients at high risk of fracture by the short versus long term prediction models - data from the Belgian FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohort.

Bone reports·2023
Same author

Are there specific clinical risk factors for the occurrence of multiple fractures? The FRISBEE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE Study.

Calcified tissue international·2022

Area of Science:

  • Oncology
  • Endocrinology
  • Bone Biology

Background:

  • Tumor-induced osteolysis involves stimulated osteoclasts and inhibited bone formation, leading to uncoupled bone turnover.
  • Neoplastic hypercalcemia is critically linked to parathyroid hormone-related protein (PTHrP), which is not calcium-regulated like parathyroid hormone (PTH).

Purpose of the Study:

  • To elucidate the mechanisms of tumor-induced osteolysis and hypercalcemia.
  • To identify key cellular targets and signaling pathways involved in these processes.
  • To optimize therapeutic strategies for managing tumor-induced bone pathologies.

Main Methods:

  • Analysis of tumor secretory products' influence on osteoclast activity.
  • Investigation of osteoblast roles in tumor-induced osteolysis.
  • Evaluation of parathyroid hormone-related protein (PTHrP) in hypercalcemia pathogenesis.

Main Results:

  • Osteoclasts are key mediators of tumor-induced osteolysis, with their activity and number increased by tumor factors.
  • Osteoblasts act as crucial target cells, enhancing osteoclast function and number.
  • Optimal therapeutic dosing of pamidronate for tumor-induced hypercalcemia and osteolysis was determined to be 90 mg.

Conclusions:

  • Tumor-induced osteolysis and hypercalcemia are complex processes involving intricate interactions between tumor cells, osteoclasts, and osteoblasts.
  • Parathyroid hormone-related protein (PTHrP) is a critical factor in neoplastic hypercalcemia.
  • A 90 mg dose of pamidronate represents an optimized therapeutic regimen for these bone-related complications of cancer.

Related Experiment Videos